The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.

Related News Articles

Headline
Hospitals, health systems and other health care organizations can sign up this week to host an intern for this year's Institute for Diversity and Health Equity…
Headline
The Centers for Disease Control and the National Tuberculosis Controllers Association this week released updated recommendations for TB screening and testing…
Headline
The House Ways and Means Committee today held a hearing examining the impact of racial disparities and social determinants of health on maternal mortality.
Headline
The Centers for Medicare…
Headline
The Food and Drug Administration last week alerted health care providers and patients that batteries in certain Medtronic implantable pacemakers and cardiac…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…